Is glucocorticoid bridging therapy associated with later use of glucocorticoids and biological DMARDs during the disease course of patients with rheumatoid arthritis in daily practice? A real-world data analysis

Editorial Material Rheumatology

Three Months of Glucocorticoids in Rheumatoid Arthritis: A Bridge Too Short?

Maarten Boers

ARTHRITIS & RHEUMATOLOGY (2022)

Article Rheumatology

Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids

Michael D. George et al.

Summary: The study evaluated the variability in glucocorticoid prescribing among rheumatologists for RA treatment and found that provider preference is one of the strongest predictors of a patient's long-term glucocorticoid use.

ARTHRITIS CARE & RESEARCH (2021)

添加到收藏夹

Review Rheumatology

Glucocorticoid and opioid use in rheumatoid arthritis management

Meriah N. Moore et al.

Summary: Recent studies have shown that a significant proportion of RA patients use glucocorticoids and/or opioids long-term, with varying risks and factors influencing exposure. Opioids may lead to delays in effective treatment initiation. Evidence increasingly demonstrates toxicity associated with even low-dose glucocorticoids, and some patients may be able to discontinue them without adverse effects.

CURRENT OPINION IN RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial

Veerle Stouten et al.

Summary: The study found that intensive treatments with glucocorticoid bridging showed excellent 5-year outcomes in early rheumatoid arthritis patients. For high-risk patients, initiating COBRA-Slim was equally effective as more complex treatments, while for low-risk patients with limited need for biologics and chronic glucocorticoid use, initial MTX monotherapy was less effective compared to using COBRA-Slim.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies

Johanna Maria Maassen et al.

Summary: Primary glucocorticoid discontinuation resulted in direct loss of disease control in approximately 40% of patients, while secondary discontinuation resulted in 50% of patients losing control. Successful primary discontinuation was associated with lower Disease Activity Score at baseline and stop visit, as well as male gender (in IMPROVED).

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Liana Fraenkel et al.

Summary: This guideline provides updated recommendations for the pharmacologic management of rheumatoid arthritis, including the use of disease-modifying antirheumatic drugs (DMARDs), glucocorticoids, and considerations for high-risk populations. The recommendations are not prescriptive and should be made through a shared decision-making process based on individual values, goals, preferences, and comorbidities.

ARTHRITIS & RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology